ZHONGSHENGYAOYE(SZ:002317) Di Yi Cai Jing·2025-11-30 09:44Core Insights - The flu season is currently peaking, with a significant increase in infection rates leading to a surge in medication demand. Unlike previous years, the market is now seeing a competition between imported drugs and a variety of newly launched domestic innovative flu medications [1][5][12] - The market for flu medications is projected to grow significantly, with an expected compound annual growth rate of 20.2% from 2024 to 2028, potentially reaching a market size of 26.9 billion yuan by 2028 [12] Market Dynamics - The flu medication market is experiencing a "new vs. old" battle, as multiple new domestic drugs enter the market, challenging the dominance of traditional medications like oseltamivir, which has seen its price drop to under 2 yuan per pill due to collective procurement [1][9] - The introduction of new antiviral drugs, such as RNA polymerase inhibitors, is changing the treatment landscape, with some new drugs priced similarly to imported options, thus increasing competition [8][10] Product Launches - Several innovative flu medications have been approved for clinical use in China, including: - Isodaz (Mashurashave tablets) by Qingfeng Pharmaceutical, targeting influenza A and B [7] - Anruwei (Angladi tablets) by Zhongsheng Pharmaceutical, the first global PB2 protein inhibitor for flu treatment [7] - Jikeshou (Maseilashave tablets) by Zhengxiang Pharmaceutical, another RNA polymerase inhibitor [7] - The first year of sales for these new drugs has shown significant growth, with Mabalosave achieving 630 million yuan in sales, marking an 800% increase [10] Consumer Behavior - There is a notable increase in the sales of flu medications, with oseltamivir's sales volume rising by 237% in a week, while new drugs like Mabalosave also saw an increase of 180% [8][10] - Despite the high price of new medications, awareness and adoption among consumers remain low, with less than 5% of those aware of their flu diagnosis opting for the new generation of drugs [10] Competitive Landscape - The influx of domestic pharmaceutical companies into the flu medication market is driven by the high certainty of market demand and relatively safe R&D prospects [13] - However, this has led to concerns about product homogeneity and potential price wars, as many companies pursue similar targets in drug development [13] Future Outlook - The flu medication market is expected to continue evolving, with ongoing innovations and potential price reductions as more products enter the market and negotiations for inclusion in national insurance schemes progress [11][12]